Proteome and bioMerieux form stroke test pact
This article was originally published in Clinica
Executive Summary
Proteome Sciences has licensed to bioMerieux its blood biomarkers for stroke, for use in the latter company's lab-based diagnostic tests. bioMerieux, based in Marcy l'Etoile, France, plans to assess the markers across a "well-defined sizeable patient population".